Participate or Learn From Cutting-Edge Studies

Clinical trials are essential for advancing diabetes treatment. They evaluate new drugs, devices, and behavioral interventions to improve glucose control, prevent complications, and enhance quality of life.

Learning about these trials helps people living with diabetes, caregivers, and clinicians stay informed about emerging therapies and potential opportunities to participate under close medical supervision.

Clinical trials are not “experiments done on you” — they are carefully designed, ethically reviewed studies with safety monitoring, informed consent, and clear protocols.

Latest Clinical Trials Targeting Beta-Cell Preservation

Beta-cell preservation is a promising strategy aimed at slowing diabetes progression and maintaining natural insulin production for longer, in both type 1 and type 2 diabetes.

Key goals of these trials:

• Preserve insulin-producing beta cells in the pancreas.
• Reduce dependence on insulin injections or delay the need for insulin.
• Improve long-term glucose stability and quality of life.

Types of interventions being studied:

• Immunotherapy: Modulates the immune system to protect beta cells from autoimmune destruction, especially in early type 1 diabetes.
• Stem cell therapy: Explores regenerative approaches that may restore or replace damaged beta cells.
• Novel agents: Small molecules and biologic drugs designed to support beta-cell survival and function.

What current findings suggest:

• Some studies show a slower decline in beta-cell function when therapies are started early.
• This may delay insulin dependence or reduce the total insulin dose needed.

Why this matters for patients and families:

• Understanding these trials helps you follow promising therapies that might improve long-term outcomes.
• Participation usually involves eligibility screening, regular monitoring, and sometimes travel to specialised centres.

Investigational Drugs for Type 1 & Type 2 Diabetes

Many clinical trials are testing new medications aimed at improving glucose control, reducing complications, and making day-to-day diabetes management easier.

Type 1 diabetes trials:

• Investigational drugs that modulate the immune system to preserve residual beta-cell function.
• Combination approaches that pair immune therapies with insulin to reduce hypoglycemia and dosing frequency.

Type 2 diabetes trials:

• Novel oral drugs and next-generation SGLT2 inhibitors and GLP-1 receptor agonists.
• Therapies being tested for blood sugar control plus cardiovascular and kidney protection.
• Nanotechnology-based insulin delivery systems designed to improve absorption and potentially reduce the need for frequent injections.

Typical trial design includes:

• Randomised controlled trials (RCTs) comparing new drugs to standard care or placebo.
• Dose-finding studies to identify safe and effective dosing ranges.
• Long-term follow-up for safety, side effects, and durability of benefit.

For patients, these studies offer a preview of therapies that may become available soon and, in some cases, the chance to access new treatments under rigorous medical supervision.

New Medications for Diabetes: Pipeline for 2025

A growing pipeline of medications and advanced therapies is being explored for both type 1 and type 2 diabetes. Some are in human clinical trials, others remain earlier-stage but are moving quickly.

Type 1 Diabetes – Investigational Medications

• Abrocitinib & Ritlecitinib (JAK inhibitors):
  • Being tested in younger individuals (12–35 years) with newly diagnosed type 1 diabetes.
  • Aim to modulate the immune response and protect remaining beta cells.
  • Currently in early-phase trials for safety, dosing, and initial efficacy.
• Baricitinib (JAK1/JAK2 inhibitor):
  • Trials in newly diagnosed type 1 diabetes show potential to slow beta-cell destruction.
  • May lower insulin requirements and improve glucose stability.
  • Still investigational and not standard therapy.
• Donislecel (beta-cell transplant / cell therapy):
  • Used in very specific, severe cases (e.g., frequent severe hypoglycemia) with controlled data.
  • Ongoing trials are exploring broader use and long-term safety.
  • Some participants achieve partial insulin independence.

Type 2 Diabetes – Investigational Medications

• PATAS:
  • A novel agent designed to enhance insulin sensitivity in fat cells.
  • Aims to improve glucose control by improving how the body responds to insulin.
  • Early-phase studies are underway; larger human trials planned for 2025.
• Nanotechnology-based insulin delivery:
  • Experimental capsules or oral formulations that release insulin in response to blood glucose levels.
  • Goal: reduce or possibly remove the need for injectable insulin.
  • Currently in preclinical and early human studies.
• Orforglipron (oral GLP-1 receptor agonist):
  • Phase 3 trials show strong blood sugar and weight reductions.
  • Oral delivery may improve adherence compared with injectable GLP-1 therapies.
• Cagrilintide + Semaglutide combination:
  • Phase III trials focus on both glucose lowering and substantial weight management.
  • Long-term safety and durability of weight loss are key endpoints.

These developments point toward less invasive, more effective diabetes management — with a focus on weight, metabolic health, and organ protection alongside glucose control.

Behavioral Intervention Studies in Prediabetes

Behavioral clinical trials test non-drug strategies to prevent diabetes in people at high risk (for example, those with prediabetes or strong family history).

Common focus areas:

• Dietary interventions: Structured meal plans, portion guidance, and healthy eating education.
• Physical activity programs: Supervised exercise sessions, walking goals, and step-count monitoring.
• Education and self-management support: Digital programs, coaching, and group classes.

What trials show:

• Sustained lifestyle changes can reduce progression from prediabetes to type 2 diabetes by up to about 58% in some programs.
• Digital/app-based interventions help improve adherence and engagement.
• Participants often gain long-term skills in nutrition, movement, and self-monitoring.

Who might benefit:

• People with prediabetes who want structured, supported plans instead of “doing it alone.”
• Those motivated to contribute to prevention research while actively improving their own health.

Updates from International Diabetes Clinical Trials

Diabetes clinical trials are global, with studies running across Europe, North America, Asia, and Australia. This diversity improves the relevance of findings for different ages, ethnicities, and health systems.

Key focus areas worldwide:

• Beta-cell preservation and regeneration approaches.
• Novel drugs and combination therapies for both type 1 and type 2 diabetes.
• Digital therapeutics, wearable devices, and remote-monitoring strategies.
• Lifestyle and behavioral interventions for prevention and risk reduction.

Regulatory impact:

• Results feed into guidelines and approvals from organisations like WHO, FDA, EMA, and others.
• Strong evidence from multiple countries helps shape global standards of care.

Practical ways to stay updated:

• Check trusted registries such as ClinicalTrials.gov for ongoing studies.
• Review major research-centre trial listings (e.g. Mayo Clinic Clinical Trials – Diabetes).
• Ask your healthcare provider if there are relevant local or regional studies.

Considering Participation in a Clinical Trial

Joining a trial is a personal decision that should always involve a thorough discussion with your healthcare team.

Additional things to know:

• Trials may provide access to new therapies before they are widely available.
• You will be informed about potential risks, side effects, and time commitments.
• Understanding trial design (phase, duration, placebo vs. active treatment) helps you weigh pros and cons.

Role of caregivers:

• Help patients remember appointments, medications, and study instructions.
• Provide transportation to visits and emotional support.
• Assist in tracking outcomes and side effects between clinic visits.

Participation is always voluntary. You can withdraw at any time, and your usual medical care should continue, regardless of whether you join or leave a study.

References